KYTX

AdHuge3806

KYTX.. not a doubt in my mind.

FrontAdvance3150

Bullish on $PED & $KYTX: $PED (Pedevco) boasts zero debt & ~$11M cash , plus new Permian & D-J wells set to boost output . $KYTX (CryoMass) locks in major cannabis deals (LEEF partnership) & $1M+/yr recurring revenue streams . 🚀

oquido

They're both good for the long haul, but right now, biotechs are all about selling the news. I'd say, sell 50-70% of your shares when the news hits, or even before, and then think about getting back in when the price drops. I got into FBIO at 2.6, and totally missed KYTX at 3.6-3.7, then again at 4.1 🫠

Paciorr

Imho KYTX is a long hold but in the end it’s your call

VivaZane

KYTX going to $5.50 today? Feels like it

UnderstandingDue1549

Promising ones right now are RZLV, CGTX, FBIO Less promising but still possible HGRAF, IXHL, KYTX, ABAT

oquido

I think KYTX has a great potential, I'm waiting to see more results though, I'll may be consider entering next year.

adku_art

Here is my chatgpt: KYTX — Due Diligence Synthesis KYTX is a high-risk / high-reward biotech lottery ticket right now: • It has serious institutional & pharma backing, a strong catalyst calendar, and enough cash to deliver results without near-term financing pressure. • But with no major data yet, it’s all binary bets on 2025–2026 readouts. For a trader, KYTX looks like a catalyst swing stock (buy dips near $3.60–3.70, sell rips into resistance or into catalyst hype). For a long-term speculator, this is a call option on CAR-T in autoimmune — you risk near-total loss if trials flop, but upside is 3–5× if data validates the platform Strengths • Cash runway into 2027 → ~$200M+ cash, debt-free, enough to fund through multiple readouts. • Rich catalyst calendar (late 2025–2026) → MS & RA IITs (Sep/Oct 2025), MG Phase 2 interim (Q4 2025), KYV-102 IND (Q4 2025), SPS registrational topline + BLA (H1 2026). • Strategic partnerships → Gilead, Intellia, Oxford Biomedica, ElevateBio, Verily, Charité → strong external validation + de-risked manufacturing. • Institutional backing → Vida Ventures, Bain, Novo, BlackRock, Vanguard, plus ~10% stake from Gilead → meaningful “smart money” presence. • Potential first-mover advantage → Could become the first CAR-T approved in autoimmune disease (SPS in 2026). ⸻

adku_art

Here is my chatgpt: KYTX — Due Diligence Synthesis KYTX is a high-risk / high-reward biotech lottery ticket right now: • It has serious institutional & pharma backing, a strong catalyst calendar, and enough cash to deliver results without near-term financing pressure. • But with no major data yet, it’s all binary bets on 2025–2026 readouts. For a trader, KYTX looks like a catalyst swing stock (buy dips near $3.60–3.70, sell rips into resistance or into catalyst hype). For a long-term speculator, this is a call option on CAR-T in autoimmune — you risk near-total loss if trials flop, but upside is 3–5× if data validates the platform Strengths • Cash runway into 2027 → ~$200M+ cash, debt-free, enough to fund through multiple readouts. • Rich catalyst calendar (late 2025–2026) → MS & RA IITs (Sep/Oct 2025), MG Phase 2 interim (Q4 2025), KYV-102 IND (Q4 2025), SPS registrational topline + BLA (H1 2026). • Strategic partnerships → Gilead, Intellia, Oxford Biomedica, ElevateBio, Verily, Charité → strong external validation + de-risked manufacturing. • Institutional backing → Vida Ventures, Bain, Novo, BlackRock, Vanguard, plus ~10% stake from Gilead → meaningful “smart money” presence. • Potential first-mover advantage → Could become the first CAR-T approved in autoimmune disease (SPS in 2026). ⸻ Weaknesses / Risks • No readouts yet → All catalysts are forward-looking; nothing validated clinically at scale. • Rising cash burn → ~$75M in 6M 2025 vs. $49M prior year; raises dilution risk despite runway. • Volatility → Weekly swings >14%, underperforming biotech peers; moves heavily on sentiment. • Execution risk → Scaling CAR-T for autoimmune is unproven compared to oncology. • Insiders not buying → They hold large stakes, but no open-market insider buys in past year (only option grants).

yellowLantern

There's always a non-zero chance of anything. There's always a chance a meteor will plummet through the atmosphere and wipe out half the earth. But I would place a KYTX acquisition as incredibly unlikely. Arcellx is the more likely acquisition (have friends that work there as well). Already partnered with Kite, an oncology product, and has some promising data. But again, everything with these biotech acquisitions hinges on data.

yellowLantern

First off, Gilead is an HIV company first, that's where the money making is. They tried to pivot to oncology under Daniel O' Day with Trodelvy. Before that it was the Kite acquisition for CAR-T. I've worked for both those franchises and also at Genentech where Gilead extensively poached. Gilead does not have the foundation or expertise for the CAR-T therapies offered by KYTX. KYTX is not oncology, it's MS and Myasthenia gravis etc. it's just not an expertise fit. Kite already bought something, my old coworkers there are focused on oncology, not new therapeutic indications

tupac_amaru

is KYTX just about the earnings report or is there another catalyst?

oquido

$KYTX and $OLTK both likely to have quite exciting week.

Gydvinn

I am actually looking at KYTX, nobody talks about it so thats a positive lol. They seem to have a huge potential and backing. They also have fast track status according to their website.

Due-Perspective-3197

KYTX It could either 10x or go to zero!

DJmysteryDrug

I'm thinking about putting $10k into 3 different stocks that recently went public. CBLL PMNT and KYTX. They seem to all be strong buy positions based on analysts predictions. Thoughts?

Koog330

KYTX and GPCR. Clickbait is lame.